Preclinical studies have demonstrated that rolipram, a PDE4 inhibitor, promotes hippocampal CREB phosphorylation, reverses memory deficits, and boosts BDNF expression in AD models [99]. This evidence concerns the gene BDNF and Alzheimer disease.